For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Supporting our customers and employees during the COVID-19 pandemic. Read more

The tumor microenvironment: an interplay of the tumor, stromal cells and immune system

Related

  • Immunohistochemistry application guide
    • Apoptosis Assay Kits
      • Tumor microenvironment resources
        • VEGF interactive pathway
          • TGFβ interactive pathway
            • The role of VEGF in angiogenesis

              The tumor microenvironment (TME) consists of various support cells subverted by the cancer cells to assist in the progression of the tumor. Learn more about the complex interplay of the tumor, stromal cells and immune cells within the TME. 

              Download our tumor microenvironment and the immune system poster, here.


              ​​​​​​​Contents

              • Tumor microenvironment - an overview
              • ​"Seed and soil" hypothesis of tumor microenvironment
              • Role of the tumor microenvironment during vascularization
              • Role of growth factors in the tumor microenvironment
              • Contribution of immune cells to the tumor microenvironment
              • ​References

              ​​​​Tumor microenvironment – an overview 

              Cancerous cells have been the central focus for cancer research for decades as they allow tumors to autonomously grow and survive. However, malignant cells alone are far from the complete picture as tumors require support from a variety of surrounding cells. Malignant and non-malignant cells co-operate to promote tumor growth, resist cell death, induce angiogenesis, invade tissues and form metastases, all while avoiding the careful surveillance of the immune system1.

              To develop a robust support system, malignant cells must recruit non-malignant cells from within the stromal tissue that would otherwise act to inhibit cancer development. Key stromal cells include cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs) and vascular endothelial cells2. These cells interact with one another and the extracellular matrix (ECM) in a zone known as the tumor microenvironment (TME).

              The process of recruiting and maintaining non-malignant cells involves complex inter- and intracellular signaling between malignant and stromal cells. Cancer cells aberrantly express cytokines, chemokines and growth factors, which stimulate supporting cells to secrete further bioactive molecules. These molecules can act in an autocrine, paracrine or juxtacrine manner to aid processes crucial for cancer development, such as tumor vascularization, metastasis and immune avoidance.

              ​​​​"Seed and soil" hypothesis of tumor microenvironment

              The interaction between the host and the cancer cell was first proposed by a 19th century English surgeon, Stephen Paget, with his “seed and soil” hypothesis. He argued that cancer cells (“the seeds”) selectively metastasize to neoplastic-promoting niches (“soil”).

              After "seeding", cancer cells actively corrupt their microenvironment. This is achieved by cancer cells releasing paracrine growth factors, cytokines, and metabolites. These factors influence the generation of de novo vasculature for oxygen supply to the tumor, perturbation of signaling and metabolism in the surrounding stroma as well as protection of cancer cells from the immune surveillance. These changes to the microenvironment create a niche for the cancer cells that is permissive for their survival as well as growth. The TME is also clinically relevant as it can affect a cancer patient's prognosis and potentially confer drug-resistance, resulting in potential relapse and metastasis.

                Role of the tumor microenvironment during vascularization

                Similar to body organs, a growing tumor also requires a supply of blood to provide oxygen and blood-borne mitogens and remove toxic metabolites. Consequently, angiogenesis (the formation of new blood vessels) and vasculogenesis (the reorganization of existing blood vessels) are essential for tumor growth.

                The TME plays an essential role in the formation and maintenance of tumor blood vessels. Multiple growth factors and cytokines co-operate to inhibit anti-angiogenic pathways and promote pro-angiogenic signaling. Key factors include vascular endothelial growth factors (VEGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF) and transforming growth factor-β (TGFβ).

                Remodeling of the ECM, a protein network that holds stromal cells in place, is essential to accommodate the newly formed vessels. Fibroblasts and supporting immune cells release serine and cysteine proteases as well as metalloproteases that catalyze this restructuring. Also, these proteases can free additional mitogens that are sequestered in the ECM, further stimulating tumor growth1.

                Tumor-associated blood vessels are essential for tumor growth and aid metastasis and immune avoidance.

                Firstly, blood vessels that form in and around tumors are disordered and unstable, due to chronic activation of angiogenic pathways. They also display a ‘leaky’ morphology as a result of poor endothelial cell junctions and limited pericyte coverage3. This structure facilitates the accumulation of tumor-supporting immune cells and permits malignant cells to metastasize to different parts of the body.

                Secondly, during normal immune surveillance, high endothelial venules (HEVs) provide an essential means of access of cytotoxic immune cells. However, tumor-associated vessels lack HEVs, resulting in the failure of cytotoxic immune cells (eg natural killer cells, cytotoxic T lymphocytes, etc) to accumulate within the TME to kill the cancer cells4.

                • Monitor angiogenesis using our in vitro angiogenesis assay kit.
                • Read our article on VEGF in angiogenesis.

                Role of growth factors in the tumor microenvironment 

                Tumor-supporting cells permit the proliferation and escape of malignant cells into the bloodstream, allowing them to form metastases. For example, as well as promoting angiogenesis, VEGF signaling can loosen tight junctions between endothelial cells, enabling migration of cancer cells into the blood stream5.

                Other growth factors also aid cancer cell survival, proliferation, invasion and metastasis. For example, EGF signaling has an important role both in cancer progression and the epithelial-to-mesenchymal transition (EMT), essential for metastasis. Along with over-production of EGF, aberrant EGF signaling can be triggered by over-expression of the membrane-bound receptor of EGF, EGFR, either by gene mutation or hypoxia6.

                PDGF can act as a chemo-attractant for CAFs, which aid tumor development by creating the permissive stroma that is critical for tumor survival7. CAFs can secrete multiple factors that potentiate tumor progression, including HGF and TGFβ. HGF activates the c-Met receptor and stimulates proliferation and invasion8. TGFβ activates EMT pathways in cancer cells, making them more invasive and likely to metastasize, and can also inhibit cytotoxic immune cells from killing cancer cells9.

                • Track changes in cytokine, chemokine and growth factor expression with our antibody arrays.

                ​Contribution of immune cells to the tumor microenvironment 

                Under normal conditions, the immune system acts as our ally, clearing pathogens and preventing disease. However, cells of the immune system can be recruited by tumors to become our enemy from within.

                Cancerous lesions contain a wide diversity of lymphoid and myeloid lymphocytes. Instead of inducing cell death, these hijacked tumor-associated immune cells promote cancer progression by secreting growth signals and proteases, which stimulate cancer cells growth and the formation of tumor blood vessels. Important factors include interleukins (ILs), chemokines, tumor necrosis factor-α (TNFα), VEGF, EGF, FGF, PDGF and TGFβ. The persistent expression of these factors by tumor-supporting immune cells stimulates cancer cell growth and the formation of tumor blood vessels1.

                Tumor growth also requires successful immune avoidance. How does the TME help malignant cells escape destruction by cells of the immune system?

                Supporting immune cells secrete a variety of factors protecting cancer cells from immune detection. Thus, CAFs secrete CXCL12, a chemokine that coats cancer cells and prevents their destruction by cytotoxic T lymphocytes10. Supporting immune cells can also promote tumor cell survival by suppressing cell death pathways. For example, TAMs express integrin a4, which forms a complex with vascular cell adhesion molecule-1 (VCAM1) that suppresses apoptosis in metastatic breast cancer cells11.

                • Download our tumor microenvironment and the immune system pathway.
                Discover more TME resources

                ​​


                References

                1. Hanahan, D., and Coussens, L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 21, 309–322 (2012).

                2. Junttila M.R., and de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 501, 346–354. (2013).

                3. McDonald, D.M., and Baluk, P. Significance of blood vessel leakiness in cancer. Cancer Res. 62, 5381–5385 (2002).

                4. Fisher, D.T., et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121, 3846–3859 (2011).

                5. Weis, S., Cui, J., Barnes, L., and Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 167, 223–229 (2004).

                6. Franovic, A., Gunaratnam L., Smith K., Robert I., Patten, D., and Lee, S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. PNAS. 104,13092–13097 (2007).

                7. Pietras, K., Pahler, J., Bergers, G., and Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5:e19. (2008).

                8. Grugan, K.D., et al. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. PNAS. 107, 11026–11031 (2010).

                9. Yu, Y., et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br. J.Cancer. 110, 724–732 (2014).

                10. Feiga, C., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. PNAS. 110, 20212–20217 (2013).

                11. Chen, Q., Zhang, X.H., and Massagué, J. Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs. Cancer Cell. 20, 538–549 (2011).

                Get resources and offers direct to your inbox Sign up
                A-Z by research area
                • Cancer
                • Cardiovascular
                • Cell biology
                • Developmental biology
                • Epigenetics & Nuclear signaling
                • Immunology
                • Metabolism
                • Microbiology
                • Neuroscience
                • Signal transduction
                • Stem cells
                A-Z by product type
                • Primary antibodies
                • Secondary antibodies
                • Biochemicals
                • Isotype controls
                • Flow cytometry multi-color selector
                • Kits
                • Loading controls
                • Lysates
                • Peptides
                • Proteins
                • Slides
                • Tags and cell markers
                • Tools & Reagents
                Help & support
                • Support
                • Make an Inquiry
                • Protocols & troubleshooting
                • Placing an order
                • RabMAb products
                • Biochemical product FAQs
                • Training
                • Browse by Target
                Company
                • Corporate site
                • Investor relations
                • Company news
                • Careers
                • About us
                • Blog
                Events
                • Tradeshows
                • Conferences
                International websites
                • abcam.cn
                • abcam.co.jp

                Join with us

                • LinkedIn
                • facebook
                • Twitter
                • YouTube
                • Terms of sale
                • Website terms of use
                • Cookie policy
                • Privacy policy
                • Legal
                • Modern slavery statement
                © 1998-2022 Abcam plc. All rights reserved.